Helicobacter therapeutic

Abstract

The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.

1 . A method of treating or preventing  Helicobacter pylori -induced inflammation in a subject, the method comprising administering to the subject a bacterial HtrA polypeptide, wherein the bacterial HtrA polypeptide comprises an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 1-6. 
     
     
         2 . The method of  claim 1 , wherein the method comprises administering a pharmaceutical composition comprising the bacterial HtrA polypeptide and a pharmaceutically acceptable excipient and/or adjuvant. 
     
     
         3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein the bacterial HtrA polypeptide comprises an amino acid sequence at least 95% identical to any one of SEQ ID NOs:1-6. 
     
     
         5 . The method of  claim 1 , wherein the  Helicobacter pylori -induced inflammation is gastritis and/or duodenitis. 
     
     
         6 . The method of  claim 5 , wherein the gastritis is atrophic gastritis. 
     
     
         7 - 25 . (canceled) 
     
     
         26 . A method of treating or preventing a disease caused by  Helicobacter pylori  infection in a subject, the method comprising administering to the subject a bacterial HtrA polypeptide, wherein the bacterial HtrA polypeptide comprises an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 1-6. 
     
     
         26 A. The method of  claim 26 , wherein the method comprises administering to the subject a pharmaceutical composition comprising the bacterial HtrA polypeptide. 
     
     
         27 . The method of  claim 26 , wherein the bacterial HtrA polypeptide comprises an amino sequence at least 95% identical to any one of SEQ ID NOs:1-6. 
     
     
         28 . The method of claim  26 A, wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient and/or adjuvant 
     
     
         29 . The method of  claim 26 , wherein the disease caused by  Helicobacter pylori  infection is inflammation, gastritis, gastric ulcer, duodenal ulcer, gastric cancer, and/or mucosa-associated-lymphoid-tissue (MALT) lymphoma. 
     
     
         30 . The method of  claim 1 , wherein the bacterial HtrA polypeptide is an enteropathogenic bacterial HtrA polypeptide. 
     
     
         31 . The method of  claim 30 , wherein the enteropathogenic bacterial HtrA polypeptide is selected from the group consisting of  Helicobacter pylori  HtrA,  Escherichia coli  HtrA,  Shigella flexneri  HtrA, and  Campylobacter jejuni  HtrA. 
     
     
         32 . The method of  claim 26 , wherein the bacterial HtrA polypeptide is an enteropathogenic bacterial HtrA polypeptide. 
     
     
         33 . The method of  claim 32 , wherein the enteropathogenic bacterial HtrA polypeptide is selected from the group consisting of  Helicobacter pylori  HtrA,  Escherichia coli  HtrA,  Shigella flexneri  HtrA, and  Campylobacter jejuni  HtrA.